Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
MC 1742 is a potent class I and IIb HDAC inhibitor (IC50 values are 7, 20, 40, 100, 110 and 610 nM for HDAC6, HDAC3, HDAC10, HDAC1, HDAC2 and HDAC8, respectively). Suppresses proliferation and induces apoptosis of sarcoma cancer stem cells (CSCs) at concentrations >500 nM. Also induces osteogenesis in sarcoma CSCs at concentrations of 25 - 500 nM.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 395.47. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.53 mL||12.64 mL||25.29 mL|
|5 mM||0.51 mL||2.53 mL||5.06 mL|
|10 mM||0.25 mL||1.26 mL||2.53 mL|
|50 mM||0.05 mL||0.25 mL||0.51 mL|
References are publications that support the biological activity of the product.
Di Pompo et al (2015) Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells. J.Med.Chem. 58 4073 PMID: 25905694
Mai et al (2008) Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. Bioorg.Med.Chem.Lett. 18 2530 PMID: 18381238
Mai et al (2006) Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J.Med.Chem. 49 6046 PMID: 17004718
If you know of a relevant reference for MC 1742, please let us know.
Keywords: MC 1742, MC 1742 supplier, MC1742, HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, inhibitors, inhibits, histone, deacetylases, class, II, IIa, epigenetics, cancer, stem, cells, CSCs, osteogenic, differentiation, Cancer, Stem, Cells, Class, I, HDACs, 5727, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for MC 1742. Do you know of a great paper that uses MC 1742 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review MC 1742 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.